You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hepatocellular carcinoma (HCC)

Showing 26 - 50 of 9,731
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Non-resectable Trial in France (Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Bordeaux, France
  • +5 more
Jun 12, 2023

Carcinoma, Hepatocellular, Hepatic Carcinoma, Hepatocellular Cancer Trial in Hannover (Nivolumab, TACE)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • +2 more
  • Hannover, Germany
    Medizinische Hochschule Hannover, Klinik für Gastroenterologie,
Nov 21, 2022

Hepatocellular Carcinoma (HCC) Trial in Beijing (¹³C-Octanoate Breath Test)

Completed
  • Hepatocellular Carcinoma (HCC)
  • ¹³C-Octanoate Breath Test
  • Beijing, China
  • +1 more
Dec 19, 2022

Hepatocellular Carcinoma, Fibrolamellar Carcinoma Trial in Daegu, Seoul (KAT-101, KAT-201)

Recruiting
  • Hepatocellular Carcinoma
  • Fibrolamellar Carcinoma
  • Daegu, Korea, Republic of
  • +2 more
Oct 30, 2022

Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial run by the NCI (durvalumab,

Recruiting
  • Hepatocellular Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Tumors Trial in Boston (ET140203 T Cells)

Recruiting
  • Hepatoblastoma
  • +5 more
  • ET140203 T Cells
  • Boston, Massachusetts
    Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Aug 12, 2022

s of a-fetoprotein Score in Real Life for Patient Selection for

Completed
  • Hepatocellular Carcinoma
  • Data collecting
  • Grenoble, France
    University Hospital, Grenoble Alpes
May 31, 2022

ADVANCED HEPATOCELLULAR CARCINOMA (HCC) Trial in Philadelphia (Galunisertib 150mg by mouth twice a day, Stereotactic Body

Completed
  • ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
  • Galunisertib 150mg by mouth twice a day
  • Stereotactic Body Radiotherapy (SBRT)
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Mar 10, 2022

Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Tumor Trial in Duarte (ECT204 T cells)

Recruiting
  • Hepatocellular Carcinoma
  • +3 more
  • ECT204 T cells
  • Duarte, California
  • +1 more
Jan 9, 2023

Hepatocellular Carcinoma Trial in Beijing (Rulonilimab+Lenvatinib, Rulonilimab +Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Jun 2, 2022

Locally Advanced Hepatocellular Carcinoma Trial in Singapore (SIRT-Y90 with Atezolizumab + Bevacizumab, SIRT-Y90 with Placebo

Recruiting
  • Locally Advanced Hepatocellular Carcinoma
  • SIRT-Y90 with Atezolizumab + Bevacizumab
  • SIRT-Y90 with Placebo (IV)
  • Singapore, Singapore
  • +1 more
Jan 26, 2023

Hepatocellular Carcinoma Trial in Hong Kong (TACE)

Recruiting
  • Hepatocellular Carcinoma
  • TACE
  • Hong Kong, Hong Kong
    Department of Imaging and Interventional Radiology, Prince of Wa
Oct 19, 2022

Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic

Enrolling by invitation
  • Hepatocellular Carcinoma
  • Sarcopenia
  • Diagnostic Test: gait speed; ct scan; grip strength and chair stand test
  • Wenzhou, Zhejiang, China
    Gang Chen
Jul 10, 2022

Hepatocellular Carcinoma Trial in Brussels (Prolarix (tretazicar co-administered with caricotamide))

Terminated
Has Results
  • Hepatocellular Carcinoma
  • Prolarix (tretazicar co-administered with caricotamide)
  • Brussels, Belgium
    Cliniques Universitaires Saint-Luc
Jul 13, 2022

Post-orthotopic Liver Transplantation, Hepatocellular Carcinoma Recurrent Trial in Nanjing (Bevacizumab Biosimilar IBI305)

Not yet recruiting
  • Post-orthotopic Liver Transplantation
  • Hepatocellular Carcinoma Recurrent
  • Bevacizumab Biosimilar IBI305
  • Nanjing, Jiangsu, China
    Jiangsu Province Hospital
May 5, 2022

Utilization of MAsS in Patients Undergoing LT for HCC

Recruiting
  • NAFLD
  • +5 more
    • New York, New York
      Columbia University Irving Medical Center
    Jun 29, 2022

    Postoperative Outcomes in Chinese HCC Patients Treated With

    Recruiting
    • Hepatocellular Carcinoma
      • Shanghai, Shanghai, China
        Zhongshan Hospital, Fudan University
      Aug 1, 2023

      Liver Cancer Trial in Houston (Bevacizumab, Erlotinib)

      Completed
      Has Results
      • Liver Cancer
      • Houston, Texas
        University of Texas MD Anderson Cancer Center
      Nov 3, 2022

      Hepatocellular Carcinoma (HCC) Trial in Taiwan, United States (IA therapy of HCC with CSR02-Fab-TF)

      Recruiting
      • Hepatocellular Carcinoma (HCC)
      • IA therapy of HCC with CSR02-Fab-TF
      • Saint Louis, Missouri
      • +6 more
      Aug 16, 2022

      Hepatocellular Carcinoma Trial in China (E-TACE)

      Not yet recruiting
      • Hepatocellular Carcinoma
      • E-TACE
      • Kaifeng, Henan, China
      • +26 more
      Sep 4, 2023

      Therapeutic Effects and Clinical Prognosis After HAIC for

      Recruiting
      • Hepatocellular Carcinoma
      • Search of factors predicting therapeutic effects and prognosis
      • Guangzhou, Guangdong, China
        Department of Minimally Invasive and Interventional Radiology, L
      Jun 7, 2022

      Carcinoma, Hepatocellular, Metabolic Syndrome Trial in Lecce (Liver resection and simultaneous sleeve gastrectomy for HCC

      Recruiting
      • Carcinoma, Hepatocellular
      • Metabolic Syndrome
      • Liver resection and simultaneous sleeve gastrectomy for HCC induced by metabolic syndrome
      • Liver resection for HCC induced by metabolic syndrome
      • Lecce, Italy
        Ospedale Vito Fazzi
      Sep 23, 2023

      Hepatocellular Carcinoma Trial in Baltimore (Nivolumab, Relatlimab)

      Recruiting
      • Hepatocellular Carcinoma
      • Baltimore, Maryland
        Sidney Kimmel Comprehensive Cancer Center
      Mar 3, 2022

      Safety of ICIs and TKIs Therapy for HCC

      Recruiting
      • Hepatocellular Carcinoma
      • +2 more
      • Lenvatinib Oral Product
      • +2 more
      • Wuhan, Hubei, China
        Tongji Hospital, Tongji Medical College, Huazhong University of
      Jun 11, 2022

      Prognostic Models for HCC Based on Tumor Micronecrosis

      Recruiting
      • Hepatocellular Carcinoma
      • observing whether HCC patients having tumor micronecrosis
      • Hangzhou, Zhejiang, China
        the First Affiliated Hospital, School of Medicine, Zhejiang Univ
      Apr 27, 2023